Hisico compound vitamin injection (13) is planned to be included in the priority review, with an R & D investment of 14.09 million yuan!

Today, hispec Pharmaceutical Group Co., Ltd released a notice saying that on December 25, 2018, the company learned that the compound vitamin injection (13) of Liaoning hispec Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has entered the list of "publicity of proposed priority review varieties" issued by the drug review center of the State Food and drug administration Announcement content display Compound vitamin injection (13) is a kind of multi vitamins for injection, which contains a variety of water-soluble vitamins and a variety of fat soluble vitamins The utility, quality and safety of the 13 kinds of multivitamins are greatly improved, and the use is more convenient, which reduces the chance of artificial preparation error and cross contamination, increases the compliance of patients with drugs, and provides a good guarantee for clinical treatment The original manufacturer of compound vitamin injection (13) is Sandoz Canada Inc at present, it has not been imported or produced in China The application for drug registration of compound vitamin injection (13) submitted by HISCO to the State Drug Administration on July 5, 2018 was accepted Up to now, the company has invested 14.09 million yuan in the R & D project of compound vitamin injection (13) The following is the full text of the announcement: